These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

875 related items for PubMed ID: 11827484

  • 1. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
    Nioche P, Liu WQ, Broutin I, Charbonnier F, Latreille MT, Vidal M, Roques B, Garbay C, Ducruix A.
    J Mol Biol; 2002 Feb 01; 315(5):1167-77. PubMed ID: 11827484
    [Abstract] [Full Text] [Related]

  • 2. Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.
    Rahuel J, García-Echeverría C, Furet P, Strauss A, Caravatti G, Fretz H, Schoepfer J, Gay B.
    J Mol Biol; 1998 Jun 19; 279(4):1013-22. PubMed ID: 9642078
    [Abstract] [Full Text] [Related]

  • 3. Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide.
    Ogura K, Tsuchiya S, Terasawa H, Yuzawa S, Hatanaka H, Mandiyan V, Schlessinger J, Inagaki F.
    J Mol Biol; 1999 Jun 11; 289(3):439-45. PubMed ID: 10356320
    [Abstract] [Full Text] [Related]

  • 4. The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif.
    Lewitzky M, Kardinal C, Gehring NH, Schmidt EK, Konkol B, Eulitz M, Birchmeier W, Schaeper U, Feller SM.
    Oncogene; 2001 Mar 01; 20(9):1052-62. PubMed ID: 11314042
    [Abstract] [Full Text] [Related]

  • 5. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1.
    Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D.
    Nature; 1993 May 06; 363(6424):83-5. PubMed ID: 8479540
    [Abstract] [Full Text] [Related]

  • 6. Gi-mediated activation of the Ras/MAP kinase pathway involves a 100 kDa tyrosine-phosphorylated Grb2 SH3 binding protein, but not Src nor Shc.
    Kranenburg O, Verlaan I, Hordijk PL, Moolenaar WH.
    EMBO J; 1997 Jun 02; 16(11):3097-105. PubMed ID: 9214627
    [Abstract] [Full Text] [Related]

  • 7. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2.
    Xu XX, Yi T, Tang B, Lambeth JD.
    Oncogene; 1998 Mar 26; 16(12):1561-9. PubMed ID: 9569023
    [Abstract] [Full Text] [Related]

  • 8. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
    Zhang T, Ma J, Cao X.
    Biochem J; 2003 Dec 01; 376(Pt 2):457-64. PubMed ID: 14498832
    [Abstract] [Full Text] [Related]

  • 9. Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs.
    Liu WQ, Vidal M, Olszowy C, Million E, Lenoir C, Dhôtel H, Garbay C.
    J Med Chem; 2004 Feb 26; 47(5):1223-33. PubMed ID: 14971902
    [Abstract] [Full Text] [Related]

  • 10. Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain.
    Liu WQ, Vidal M, Gresh N, Roques BP, Garbay C.
    J Med Chem; 1999 Sep 09; 42(18):3737-41. PubMed ID: 10479306
    [Abstract] [Full Text] [Related]

  • 11. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.
    Furet P, Gay B, Caravatti G, García-Echeverría C, Rahuel J, Schoepfer J, Fretz H.
    J Med Chem; 1998 Aug 27; 41(18):3442-9. PubMed ID: 9719597
    [Abstract] [Full Text] [Related]

  • 12. Molecular dynamics, free energy, and SPR analyses of the interactions between the SH2 domain of Grb2 and ErbB phosphotyrosyl peptides.
    Suenaga A, Hatakeyama M, Ichikawa M, Yu X, Futatsugi N, Narumi T, Fukui K, Terada T, Taiji M, Shirouzu M, Yokoyama S, Konagaya A.
    Biochemistry; 2003 May 13; 42(18):5195-200. PubMed ID: 12731860
    [Abstract] [Full Text] [Related]

  • 13. Thermodynamic and structural analysis of phosphotyrosine polypeptide binding to Grb2-SH2.
    McNemar C, Snow ME, Windsor WT, Prongay A, Mui P, Zhang R, Durkin J, Le HV, Weber PC.
    Biochemistry; 1997 Aug 19; 36(33):10006-14. PubMed ID: 9254595
    [Abstract] [Full Text] [Related]

  • 14. A new function for phospholipase C-gamma1: coupling to the adaptor protein GRB2.
    Pei Z, Maloney JA, Yang L, Williamson JR.
    Arch Biochem Biophys; 1997 Sep 01; 345(1):103-10. PubMed ID: 9281317
    [Abstract] [Full Text] [Related]

  • 15. Nuclear magnetic resonance solution structure of the growth factor receptor-bound protein 2 Src homology 2 domain.
    Thornton KH, Mueller WT, McConnell P, Zhu G, Saltiel AR, Thanabal V.
    Biochemistry; 1996 Sep 10; 35(36):11852-64. PubMed ID: 8794768
    [Abstract] [Full Text] [Related]

  • 16. Solution structure of Grb2 reveals extensive flexibility necessary for target recognition.
    Yuzawa S, Yokochi M, Hatanaka H, Ogura K, Kataoka M, Miura K, Mandiyan V, Schlessinger J, Inagaki F.
    J Mol Biol; 2001 Feb 23; 306(3):527-37. PubMed ID: 11178911
    [Abstract] [Full Text] [Related]

  • 17. MAP kinase phosphorylation of mSos1 promotes dissociation of mSos1-Shc and mSos1-EGF receptor complexes.
    Rozakis-Adcock M, van der Geer P, Mbamalu G, Pawson T.
    Oncogene; 1995 Oct 05; 11(7):1417-26. PubMed ID: 7478566
    [Abstract] [Full Text] [Related]

  • 18. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.
    Lung FD, Tsai JY.
    Biopolymers; 2003 Oct 05; 71(2):132-40. PubMed ID: 12767115
    [Abstract] [Full Text] [Related]

  • 19. The amino-terminal Src homology 2 domain of phospholipase C gamma 1 is essential for TCR-induced tyrosine phosphorylation of phospholipase C gamma 1.
    Stoica B, DeBell KE, Graham L, Rellahan BL, Alava MA, Laborda J, Bonvini E.
    J Immunol; 1998 Feb 01; 160(3):1059-66. PubMed ID: 9570517
    [Abstract] [Full Text] [Related]

  • 20. Molecular and cellular analysis of Grb2 SH3 domain mutants: interaction with Sos and dynamin.
    Vidal M, Goudreau N, Cornille F, Cussac D, Gincel E, Garbay C.
    J Mol Biol; 1999 Jul 16; 290(3):717-30. PubMed ID: 10395825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.